Metoprololsuccinat Pharmaclan (Metoprolol Succinate)

Metoprolol succinate selectively blocks β1‑adrenergic receptors located primarily in the heart. By inhibiting the action of adrenaline and noradrenaline at these sites, it reduces heart rate, contractile force, and conduction velocity, which together lower cardiac output and oxygen demand, providing therapeutic benefit in cardiovascular disease.

The appropriate dose of Metoprololsuccinat Pharmaclan is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage adjustments may be required for renal or hepatic impairment, and the medication is typically titrated to achieve target blood pressure or heart‑rate goals.

Safety data for metoprolol succinate in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate each case individually and discuss alternatives when appropriate.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide your institutional or trade credentials. GNH India supplies hospitals, pharmacies and procurement teams worldwide, then responds with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Metoprolol succinate is a cardio‑selective (β1‑selective) beta‑blocker with a long‑acting formulation, allowing once‑daily dosing. Compared with non‑selective agents such as propranolol, it has a lower risk of bronchospasm in patients with reactive airway disease. Its pharmacokinetic profile provides more stable plasma concentrations than short‑acting beta‑blockers.

Store Metoprololsuccinat Pharmaclan at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture, excessive heat and direct sunlight. Do not refrigerate or freeze unless specifically instructed by the manufacturer.

Metoprololsuccinat Pharmaclan is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a full glass of water and follow the dosing schedule prescribed by their healthcare professional to maintain consistent blood levels.

Serious adverse events may include marked bradycardia, severe hypotension, worsening heart‑failure symptoms, and bronchospasm in susceptible individuals. Prompt medical attention is required if patients experience fainting, chest pain, difficulty breathing, or a sudden drop in blood pressure.

Metoprololsuccinat Pharmaclan is contraindicated in patients with known hypersensitivity to metoprolol or any excipients, those with severe bradycardia (heart rate < 45 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, and individuals in cardiogenic shock. Caution is also advised for patients with uncontrolled asthma or severe peripheral vascular disease.